Université Paris Descartes, Faculté de Médecine, INSERM U1151; Service des explorations fonctionnelles, hôpital Necker-enfants malades, Assistance Publique-Hôpitaux de Paris, 149, rue de Sèvres, 75015 Paris, France.
Diabetes Metab. 2014 Dec;40(6 Suppl 1):S12-6. doi: 10.1016/S1262-3636(14)72690-4.
Under physiological conditions, the kidneys contribute to glucose homoeostasis by producing glucose by gluconeogenesis and preventing glucose loss in urine. The glucose filtered by the glomeruli is completely reabsorbed in the renal proximal tubule. Renal gluconeogenesis produces 25% of the circulating glucose in the postabsorptive state, while the amount of glucose reabsorbed by the kidneys largely exceeds the quantity synthesized by kidney gluconeogenesis. Sodium-glucose cotransporter type 2 (SGLT-2) and glucose transporter 2 (GLUT2) carry out more than 90% of renal glucose uptake. In diabetes, both gluconeogenesis and renal glucose reabsorption are increased. The augmentation of glucose uptake in diabetes is due to the overexpression of renal glucose transporters SGLT-2 and GLUT2 in response to the increase in expression of transcription activator hepatic nuclear factor 1-alpha (HNF1α). The rise in glucose uptake contributes to hyperglycaemia and induces glomerular hyperfiltration by increasing sodium and water reabsorption in the proximal tubule that, in turn, modifies urine flux at the macula densa. SGLT-2 inhibitors improve glycaemic control and prevent renal hyperfiltration in diabetes. Loss of SGLT-2 transporter function is a benign state characterized by glycosuria. In contrast, mutations of other glucose transporters expressed in the kidney are responsible for severe disorders.
在生理条件下,肾脏通过糖异生产生葡萄糖并防止尿液中葡萄糖丢失,从而有助于葡萄糖的体内平衡。肾小球滤过的葡萄糖在肾近端小管中被完全重吸收。在吸收后状态下,肾糖异生产生循环葡萄糖的 25%,而肾脏重吸收的葡萄糖量大大超过肾糖异生合成的葡萄糖量。钠-葡萄糖协同转运蛋白 2 (SGLT-2) 和葡萄糖转运蛋白 2 (GLUT2) 进行超过 90%的肾脏葡萄糖摄取。在糖尿病中,糖异生和肾葡萄糖重吸收均增加。糖尿病中葡萄糖摄取的增加是由于转录激活因子肝核因子 1-α (HNF1α) 表达增加导致肾脏葡萄糖转运蛋白 SGLT-2 和 GLUT2 的过度表达所致。葡萄糖摄取的增加导致高血糖,并通过增加近端小管中钠和水的重吸收诱导肾小球高滤过,进而改变致密斑处的尿液流量。SGLT-2 抑制剂可改善血糖控制并预防糖尿病中的肾脏高滤过。SGLT-2 转运蛋白功能的丧失是一种良性状态,其特征为糖尿。相比之下,表达在肾脏中的其他葡萄糖转运体的突变则导致严重的紊乱。